BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Transgene to Present Additional Immunology Data From the TIME Trial With TG4010 in Patients With Advanced Lung Cancer at SITC 2017

  Transgene will be presenting a poster on additional immunology data generated from the randomized, placebo-controlled Phase 2b trial (TIME) that evaluated the combination regimen of TG4010 and chemotherapy in patients with advanced lung cancer.

  October 30, 2017

   · 

  4 min read
• Pharnext Announces Acceptance of Late Breaking Abstract at the 10th Clinical Trials on Alzheimer’s Disease Conference

  Pharnext announced that new synergy data related to PXT864, the Company’s second lead PLEODRUG in development for the treatment of Alzheimer’s disease (AD), will be presented as a late breaking poster at the 10th Clinical Trials on Alzheimer’s Disease Conference.

  October 30, 2017

   · 

  3 min read
• Mauna Kea Technologies: New CONTACT Study Analysis Demonstrates Cellvizio’s Ability to Improve the Management of Patients With Pancreatic Cysts

  Mauna Kea Technologies announced that Cellvizio was featured in several presentations at the United European Gastroenterology Week (UEGW) 2017 meeting, including a late-breaking presentation of new data from the CONTACT study of Cellvizio for the diagnosis of pancreatic cysts.

  October 30, 2017

   · 

  5 min read
• Drug Development

  Mersana Therapeutics Presents New Data on XMT-1536, a NaPi2b Targeting Antibody Drug Conjugate, at the AACR-NCI-EORTC International Conference

  Presentation highlights expanded pre-clinical data supporting the development of XMT-1536 in a broad population of patients with ovarian cancer.

  October 30, 2017

   · 

  5 min read
• Deals

  Aviragen Therapeutics and Vaxart Enter into Merger Agreement

  The merger will result in a combined company, Vaxart, focused on developing orally-delivered therapeutics and prophylactics to address a variety of viral infections.

  October 30, 2017

   · 

  11 min read
• BioCanCell Announces Exploration of Funding Round Conditioned on a Going Private Transaction and Business Development Update

  The investors have informed BioCanCell that the execution of the Private Investment is dependent on BioCanCell’s becoming a private company.

  October 30, 2017

   · 

  4 min read
• Drug Development

  Anavex Life Sciences Announces Additional Data at The Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Conference

  ANAVEX2-73 has shown to have neurorestorative effects in a model for experimental parkinsonism.

  October 30, 2017

   · 

  5 min read
• Business

  Iradimed Corporation Announces Third Quarter 2017 Financial Results

  For the third quarter ended September 30, 2017, the Company reported revenue of $5.7 million compared to $7.7 million for the third quarter 2016.

  October 30, 2017

   · 

  15 min read
• Policy

  GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Completes Rolling New Drug Application Submission to U.S. Food and Drug Administration for Epidiolex (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome and Dravet Syndrome

  GW has received Rare Pediatric Disease and Orphan Drug Designations from the FDA for Epidiolex in the treatment of both LGS and Dravet syndrome.

  October 30, 2017

   · 

  6 min read
• 

  Abbott Shows off Landmark XIENCE Stent Data

  The data was presented during a late-breaking session at the 29th Transcatheter Cardiovascular Therapeutics meeting.

  October 30, 2017

   · 

  4 min read